Guo Guangchang: Fosun Strives to Break Through in Advantageous Sectors and Reach the Global Pinnacle
Fosun International (OTC:FOSUY) Chairman Guo Guangchang outlined the company's strategic vision during its 2025 interim results presentation, emphasizing continued investment in biopharmaceuticals and focus on established advantageous sectors. The company has made significant breakthroughs in its pharmaceutical segment, with a robust pipeline of innovative drugs including Henlius products and Fosun Kite's CAR-T therapy.
Highlighting Fosun's commitment to global expansion, Guangchang emphasized the company's dedication to building global R&D, clinical, and sales capabilities. The chairman noted that establishing competitive strength requires long-term investment, citing Henlius's RMB10 billion investment over 15 years and the recent profitability of its insurance ventures.
The company maintains its vision of helping people live healthily to age 121, with a particular focus on making cancer curable through comprehensive treatment approaches combining drugs, devices, and multi-molecule therapies.
Fosun International (OTC:FOSUY) Il presidente Guo Guangchang ha illustrato la visione strategica dell’azienda durante la presentazione dei risultati semestrali 2025, sottolineando la prosecuzione degli investimenti nelle biofarmaceutiche e la focalizzazione sui settori in cui l’azienda è già avvantaggiata. Il gruppo ha registrato progressi rilevanti nel segmento farmaceutico, con un solido portafoglio di farmaci innovativi che include i prodotti Henlius e la terapia CAR-T di Fosun Kite.
Per ribadire l’impegno verso l’espansione globale, Guangchang ha enfatizzato la volontà di sviluppare capacità globali di R&S, cliniche e commerciali. Il presidente ha ricordato che costruire vantaggio competitivo richiede investimenti di lungo periodo, citando l’investimento di 10 miliardi di RMB di Henlius in 15 anni e la recente redditività delle attività assicurative.
L’azienda conserva la visione di aiutare le persone a vivere sane fino a 121 anni, con un’attenzione particolare a rendere il cancro curabile attraverso approcci terapeutici integrati che combinano farmaci, dispositivi e terapie multimolecolari.
Fosun International (OTC:FOSUY) El presidente Guo Guangchang presentó la visión estratégica de la compañía en la rueda de resultados intermedios de 2025, destacando la continuidad de la inversión en biofarmacéutica y el enfoque en sectores con ventaja consolidada. La empresa ha logrado avances importantes en su división farmacéutica, con una sólida cartera de fármacos innovadores que incluye productos de Henlius y la terapia CAR-T de Fosun Kite.
Subrayando el compromiso de Fosun con la expansión global, Guangchang remarcó la dedicación a construir capacidades globales de I+D, clínica y comercial. El presidente señaló que establecer una fortaleza competitiva requiere inversión a largo plazo, citando la inversión de 10.000 millones de RMB de Henlius durante 15 años y la reciente rentabilidad de sus negocios aseguradores.
La compañía mantiene la visión de ayudar a las personas a vivir sanas hasta los 121 años, con un énfasis particular en hacer el cáncer curable mediante enfoques integrales que combinan fármacos, dispositivos y terapias multimoleculares.
Fosun International (OTC:FOSUY) 구광창(Guo Guangchang) 회장은 2025년 중간 실적 발표에서 회사의 전략적 비전을 설명하며 바이오제약에 대한 지속적 투자와 기존에 유리한 분야에 대한 집중을 강조했습니다. 회사는 제약 부문에서 중요한 성과를 거두었으며, Henlius 제품과 Fosun Kite의 CAR-T 치료제를 포함한 탄탄한 혁신 신약 파이프라인을 보유하고 있습니다.
Fosun의 글로벌 확장 의지를 강조하며 광창 회장은 글로벌 연구개발(R&D), 임상 및 영업 역량 구축에 대한 헌신을 피력했습니다. 회장은 경쟁력을 갖추기 위해서는 장기적 투자가 필요하다고 언급하면서 Henlius의 15년에 걸친 100억 위안 투자과 보험 사업의 최근 수익성 달성을 예로 들었습니다.
회사는 사람들이 121세까지 건강하게 살도록 돕겠다는 비전을 유지하고 있으며, 약물, 기기 및 다분자 치료를 결합한 종합적 치료 접근을 통해 암을 치료 가능하게 만드는 데 중점을 두고 있습니다.
Fosun International (OTC:FOSUY) Le président Guo Guangchang a exposé la vision stratégique de l’entreprise lors de la présentation des résultats semestriels 2025, en insistant sur la poursuite des investissements dans la biopharmacie et sur la concentration dans les secteurs où elle dispose d’avantages établis. La société a réalisé des avancées significatives dans sa division pharmaceutique, avec un portefeuille robuste de médicaments innovants comprenant les produits Henlius et la thérapie CAR-T de Fosun Kite.
Souligneant l’engagement de Fosun en faveur de l’expansion mondiale, Guangchang a insisté sur la volonté de développer des capacités mondiales de R&D, cliniques et commerciales. Le président a noté que l’acquisition d’un avantage concurrentiel exige des investissements à long terme, citant l’investissement de 10 milliards de RMB par Henlius sur 15 ans et la récente rentabilité de ses activités d’assurance.
L’entreprise maintient la vision d’aider les gens à vivre en bonne santé jusqu’à 121 ans, en mettant particulièrement l’accent sur le fait de rendre le cancer guérissable grâce à des approches thérapeutiques globales combinant médicaments, dispositifs et thérapies multimoléculaires.
Fosun International (OTC:FOSUY) Vorsitzender Guo Guangchang skizzierte während der Präsentation der Halbjahresergebnisse 2025 die strategische Ausrichtung des Unternehmens und betonte die fortgesetzten Investitionen in die Biopharma-Branche sowie die Konzentration auf etablierte, vorteilhafte Sektoren. Das Unternehmen verzeichnete bedeutende Durchbrüche im Pharmabereich und verfügt über eine starke Pipeline innovativer Medikamente, darunter Produkte von Henlius und die CAR-T-Therapie von Fosun Kite.
Zur Bekräftigung von Fosuns Engagement für die globale Expansion hob Guangchang die Verpflichtung zum Aufbau globaler F&E-, klinischer und Vertriebsfähigkeiten hervor. Der Vorsitzende erklärte, dass der Aufbau wettbewerblicher Stärke langfristige Investitionen erfordere, und nannte das 10-Milliarden-RMB-Investment von Henlius über 15 Jahre sowie die jüngste Rentabilität der Versicherungssparten als Beispiele.
Das Unternehmen verfolgt weiterhin die Vision, Menschen ein gesundes Leben bis 121 Jahre zu ermöglichen, mit besonderem Fokus darauf, Krebs durch umfassende Behandlungsansätze, die Medikamente, Geräte und Mehrfachmolekültherapien kombinieren, heilbar zu machen.
- Strong pipeline of innovative drugs across multiple divisions
- Comprehensive strategic layout in health segment with global R&D capabilities
- Insurance subsidiaries entering profitability phase after long-term investment
- Strategic focus on deepening established advantageous sectors
- Extended period required for return on investments (10+ years)
- Significant capital requirements for R&D and global expansion
The interim results presentation was held in
Guo Guangchang highlighted that Fosun achieved significant breakthroughs across several business segments in the first half of 2025, particularly in the biopharmaceutical segment. Moving forward, Fosun will seize growth opportunities and aim for breakthrough progress through technology innovation.
Regarding investor concerns about innovative drug R&D, Guo Guangchang explained that within Fosun's robust pipeline, it has reserved a batch of important products. Fosun's pharmaceutical innovation will extend beyond just Henlius. It also has Fosun Kite's CAR-T therapy, along with innovative drugs from its established product divisions, all of which have immense potential.
Guo Guangchang said, "I have been emphasizing to our team that we shouldn't just sell off all our innovative drugs. Both licensing in and licensing out are important. Some products may command a high price if simply licensed out, but we are not in a rush. We should continue to advance our R&D to make these products the best in the world."
Guo Guangchang said that Fosun previously stated its vision is to help everyone to live healthily and happily to the age of 121. In particular, Fosun's self-imposed goal is that cancer should be curable. With the current trajectory of pharmaceuticals development, this increasingly feels like an achievable reality. Many cancers today are already preventable, treatable, detectable, curable, or can be managed as chronic, controllable conditions.
Guo Guangchang believes that future cancer treatment will not rely on a single approach, it will involve a combination of approaches, including drugs, devices, and multi-molecule therapies, similar to a cocktail therapy. Fosun possesses a distinct advantage in these areas due to its comprehensive strategic layout and broad industry presence in the Health segment. Future cancer treatment will require comprehensive capability, and this comprehensive capability is precisely one of Fosun Pharma's hallmark characteristics.
He emphasized that what sets Fosun apart from other Chinese pharmaceutical companies is Fosun's commitment to building its own global R&D capabilities, global clinical capabilities, and global sales capabilities. This is Fosun's unwavering mission—and the fundamental path for it to become a truly global pharmaceutical leader.
When sharing his insights on building a business, Guo Guangchang said that nowadays, it is very difficult to establish true competitive strength without at least a decade or two of effort. For example, Henlius, now 15 years old, saw its initial 10-plus years involve investments exceeding
He stated that Fosun's excitement doesn't lie in new sectors; it lies in deepening and thoroughly developing industries that it has established significant industry advantages, striving to achieve breakthroughs, accelerate growth, and ascend to the pinnacle within these mature sectors, securing a commanding global position.
Guo Guangchang said, "Even old wine needs innovation. Fosun's Shede Spirits has recently conducted innovative R&D on high-alcohol traditional baijiu and launched a new liquor with
View original content:https://www.prnewswire.com/news-releases/guo-guangchang-fosun-strives-to-break-through-in-advantageous-sectors-and-reach-the-global-pinnacle-302541984.html
SOURCE Fosun
FAQ
What is Fosun International's (FOSUY) strategy for pharmaceutical development in 2025?
How much has Fosun invested in Henlius and what are the returns?
What is Fosun's approach to cancer treatment development?
How are Fosun's insurance subsidiaries performing in 2025?
What is Fosun's global expansion strategy in pharmaceuticals?
